Product Name
WNT7A, siRNA
Full Product Name
WNT7A siRNA (Mouse)
Product Synonym Names
WNT-7A; Protein Wnt-7a
Product Gene Name
WNT7A sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P24383
Specificity
WNT7A siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse WNT7A gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of WNT7A sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
WNT7A sirna
siRNA to inhibit WNT7A expression using RNA interference
Applications Tested/Suitable for WNT7A sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for WNT7A. It may not necessarily be applicable to this product.
NCBI Accession #
NP_033553.2
[Other Products]
NCBI GenBank Nucleotide #
NM_009527.3
[Other Products]
UniProt Primary Accession #
P24383
[Other Products]
UniProt Secondary Accession #
Q80VH3; Q9DBY3[Other Products]
UniProt Related Accession #
P24383[Other Products]
Molecular Weight
38,974 Da
NCBI Official Full Name
protein Wnt-7a
NCBI Official Synonym Full Names
wingless-type MMTV integration site family, member 7A
NCBI Official Symbol
Wnt7a [Similar Products]
NCBI Official Synonym Symbols
px; tw; Wnt-7a; AI849442
[Similar Products]
NCBI Protein Information
protein Wnt-7a
UniProt Protein Name
Protein Wnt-7a
UniProt Gene Name
Wnt7a [Similar Products]
UniProt Synonym Gene Names
Wnt-7a [Similar Products]
UniProt Entry Name
WNT7A_MOUSE
UniProt Comments for WNT7A
WNT7A: Ligand for members of the frizzled family of seven transmembrane receptors. Probable developmental protein. Signaling by Wnt-7a allows sexually dimorphic development of the mullerian ducts. Defects in WNT7A are the cause of limb pelvis hypoplasia aplasia syndrome (LPHAS). A syndrome of severe deficiency of the extremities due to hypo- or aplasia of one or more long bones of one or more limbs. Pelvic manifestations include hip dislocation, hypoplastic iliac bone and aplastic pubic bones. Thoracic deformity, unusual facies and genitourinary anomalies can be present. Defects in WNT7A are a cause of Fuhrmann syndrome (FUHRS); also known as fibular aplasia or hypoplasia femoral bowing and poly- syn- and oligodactyly. Fuhrmann syndrome is a distinct limb-malformation disorder characterized also by various degrees of limb aplasia/hypoplasia and joint dysplasia. Belongs to the Wnt family.
Protein type: Secreted, signal peptide; Secreted
Cellular Component: extracellular space; proteinaceous extracellular matrix; cell surface; cell; extracellular region
Molecular Function: protein binding; frizzled binding; cytokine activity; receptor agonist activity; receptor binding
Biological Process: hindlimb morphogenesis; somatic stem cell maintenance; positive regulation of epithelial cell proliferation involved in wound healing; positive regulation of transcription, DNA-dependent; multicellular organismal development; Wnt receptor signaling pathway through beta-catenin; uterus development; cell-cell signaling; regulation of axon diameter; synapse organization and biogenesis; somatic stem cell division; chondrocyte differentiation; satellite cell activation; cartilage condensation; embryonic limb morphogenesis; cell fate commitment; skin morphogenesis; asymmetric protein localization; positive regulation of synaptogenesis; organ morphogenesis; response to estrogen stimulus; positive regulation of transcription from RNA polymerase II promoter; embryonic digit morphogenesis; negative regulation of apoptosis; embryonic forelimb morphogenesis; limb development; cell proliferation in forebrain; neurotransmitter secretion; positive regulation of JNK cascade; palate development; regulation of axonogenesis; signal transduction; embryonic hindlimb morphogenesis; negative regulation of neurogenesis; forelimb morphogenesis; central nervous system vasculogenesis; positive regulation of cell proliferation; angiogenesis; fallopian tube development; Wnt receptor signaling pathway; embryonic axis specification; satellite cell compartment self-renewal involved in skeletal muscle regeneration; cerebellar granule cell differentiation; regulation of cell proliferation; stem cell development; dorsal/ventral pattern formation; establishment of cell polarity; skeletal morphogenesis; cartilage development; reproductive structure development
Research Articles on WNT7A
1. Wnt7a is a novel regulator of ventral midbrain neurogenesis and dopaminergic neuron axon growth and guidance.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
